Compile Data Set for Download or QSAR
Report error Found 153 of affinity data for UniProtKB/TrEMBL: P05231
TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM414420((R)-7-[4-(2-ethoxycarbonyl-2-hydroxyethyl)oxy-2-me...)
Affinity DataIC50: 1nMAssay Description:1) The subcultured HCE-T was recovered and the cells were seeded at 2.0×104 cells/0.1 mL/well in a 96-well flat bottom culture plate.2) After culturi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM331838((R)-7-[4-(2-ethoxycarbonyl-2-hydroxyethyl)oxy-2-me...)
Affinity DataIC50: 1nMAssay Description:o evaluate the action of the present compounds as a GR agonist, IL-6 production inhibitory action in human corneal epithelial cell line after LPS sti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM140013(US8901310, Comparator C)
Affinity DataIC50: 1.10nMAssay Description:The glucocorticoid receptor fluorescence polarization ligand binding (GRFP) assay is used to evaluate direct binding of testing compounds to full-len...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/4/2015
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM140015(US8901310, Comparator E)
Affinity DataIC50: 1.10nMAssay Description:The glucocorticoid receptor fluorescence polarization ligand binding (GRFP) assay is used to evaluate direct binding of testing compounds to full-len...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/4/2015
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM140014(US8901310, Comparator D)
Affinity DataIC50: 1.30nMAssay Description:The glucocorticoid receptor fluorescence polarization ligand binding (GRFP) assay is used to evaluate direct binding of testing compounds to full-len...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/4/2015
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM140017(US8901310, Comparator G)
Affinity DataIC50: 2.10nMAssay Description:The glucocorticoid receptor fluorescence polarization ligand binding (GRFP) assay is used to evaluate direct binding of testing compounds to full-len...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/4/2015
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423528(US10508115, Compound If-04)
Affinity DataEC50:  2.5nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM140019(US8901310, Comparator I)
Affinity DataIC50: 2.80nMAssay Description:The glucocorticoid receptor fluorescence polarization ligand binding (GRFP) assay is used to evaluate direct binding of testing compounds to full-len...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/4/2015
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423493(US10508115, Compound Ib-12)
Affinity DataEC50:  3.77nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM65497(CC-220 (Compound 6) | US9694015, 6.4S)
Affinity DataIC50: 3.80nMT: 2°CAssay Description:The Fix buffer I was warmed up to 37° C. in an incubator or water bath prior to use. The Perm Buffer III was chilled in a 20° C. freezer prio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2018
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423530(US10508115, Compound If-06)
Affinity DataEC50:  3.80nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM140012(US8901310, Comparator B)
Affinity DataIC50: 4nMAssay Description:The glucocorticoid receptor fluorescence polarization ligand binding (GRFP) assay is used to evaluate direct binding of testing compounds to full-len...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/4/2015
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM19190((1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-...)
Affinity DataIC50: 4.20nMAssay Description:The glucocorticoid receptor fluorescence polarization ligand binding (GRFP) assay is used to evaluate direct binding of testing compounds to full-len...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/4/2015
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM140018(US8901310, Comparator H)
Affinity DataIC50: 4.30nMAssay Description:The glucocorticoid receptor fluorescence polarization ligand binding (GRFP) assay is used to evaluate direct binding of testing compounds to full-len...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/4/2015
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM419194(US10457681, Compound Ia-02 | US10487084, Compound ...)
Affinity DataEC50:  4.90nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2021
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM419194(US10457681, Compound Ia-02 | US10487084, Compound ...)
Affinity DataEC50:  4.90nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423496(US10508115, Compound Ib-17 | US10508115, Compound ...)
Affinity DataEC50:  5.11nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423488(US10508115, Compound Ib-07)
Affinity DataEC50:  5.81nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423490(US10508115, Compound Ib-09)
Affinity DataEC50:  5.91nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423480(US10508115, Compound Ia-07)
Affinity DataEC50:  6.62nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM419219(US10457681, Compound Ia-04 | US10487084, Compound ...)
Affinity DataEC50:  6.90nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Tech-nologies clear, V-bottom 384-well plate using ECHO acoustic liquid ha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM140016(US8901310, Comparator F)
Affinity DataIC50: 7nMAssay Description:The glucocorticoid receptor fluorescence polarization ligand binding (GRFP) assay is used to evaluate direct binding of testing compounds to full-len...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/4/2015
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423484(US10508115, Compound Ib-03)
Affinity DataEC50:  7.5nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM420041(US10487084, Compound Ib-02)
Affinity DataEC50:  7.55nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Tech-nologies clear, V-bottom 384-well plate using ECHO acoustic liquid ha...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
9/20/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423522(US10508115, Compound Ie-08)
Affinity DataEC50:  7.60nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423531(US10508115, Compound If-07)
Affinity DataEC50:  7.80nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423492(US10508115, Compound Ib-11)
Affinity DataEC50:  8.14nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423486(US10508115, Compound Ib-05)
Affinity DataEC50:  9.57nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM77001(3-(4-((4-(morpholinomethyl)benzyl)-oxy)-1-oxoisoin...)
Affinity DataIC50: 10nMT: 2°CAssay Description:The Fix buffer I was warmed up to 37° C. in an incubator or water bath prior to use. The Perm Buffer III was chilled in a 20° C. freezer prio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2018
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423499(US10508115, Compound Ic-01)
Affinity DataEC50:  10.1nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423477(US10508115, Compound Ia-04)
Affinity DataEC50:  10.4nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423487(US10508115, Compound Ib-06)
Affinity DataEC50:  10.7nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM483349(US10919895, Compound Ic-13)
Affinity DataEC50:  11nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2021
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423511(US10508115, Compound Id-05)
Affinity DataEC50:  12nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM419194(US10457681, Compound Ia-02 | US10487084, Compound ...)
Affinity DataEC50:  12.6nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Tech-nologies clear, V-bottom 384-well plate using ECHO acoustic liquid ha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM331841((S)-7-[4-(3-cyano-2-hydroxypropyl)oxy-2-methoxyphe...)
Affinity DataIC50: 13nMAssay Description:o evaluate the action of the present compounds as a GR agonist, IL-6 production inhibitory action in human corneal epithelial cell line after LPS sti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423510(US10508115, Compound Id-04)
Affinity DataEC50:  13nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM331841((S)-7-[4-(3-cyano-2-hydroxypropyl)oxy-2-methoxyphe...)
Affinity DataIC50: 13nMAssay Description:1) The subcultured HCE-T was recovered and the cells were seeded at 2.0×104 cells/0.1 mL/well in a 96-well flat bottom culture plate.2) After culturi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM483348(US10919895, Compound Ic-12)
Affinity DataEC50:  13nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2021
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM483339(US10919895, Compound Ic-03)
Affinity DataEC50:  14nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2021
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423509(US10508115, Compound Id-03)
Affinity DataEC50:  14nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM331840((R)-7-[4-(3-cyano-2-hydroxypropyl)oxy-2-methoxyphe...)
Affinity DataIC50: 14nMAssay Description:1) The subcultured HCE-T was recovered and the cells were seeded at 2.0×104 cells/0.1 mL/well in a 96-well flat bottom culture plate.2) After culturi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423527(US10508115, Compound If-03)
Affinity DataEC50:  14nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM331840((R)-7-[4-(3-cyano-2-hydroxypropyl)oxy-2-methoxyphe...)
Affinity DataIC50: 14nMAssay Description:o evaluate the action of the present compounds as a GR agonist, IL-6 production inhibitory action in human corneal epithelial cell line after LPS sti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423491(US10508115, Compound Ib-10)
Affinity DataEC50:  14.3nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM493082(US10981914, Compound Ia-03)
Affinity DataEC50:  14.4nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2021
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM419208(US10457681, Compound Ia-03 | US10487084, Compound ...)
Affinity DataEC50:  14.4nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM419208(US10457681, Compound Ia-03 | US10487084, Compound ...)
Affinity DataEC50:  15nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Tech-nologies clear, V-bottom 384-well plate using ECHO acoustic liquid ha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM331839((S)-7-[4-(2,4-dihydroxybutyl)oxy-2-methoxyphenyl]-...)
Affinity DataIC50: 15nMAssay Description:1) The subcultured HCE-T was recovered and the cells were seeded at 2.0×104 cells/0.1 mL/well in a 96-well flat bottom culture plate.2) After culturi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
Go to US Patent

TargetInterleukin-6(Human)
Santen Pharmaceutical

US Patent
LigandPNGBDBM423513(US10508115, Compound Id-07)
Affinity DataEC50:  15nMAssay Description:Compounds diluted in DMSO were transferred to individual wells of a Matrix Technologies clear, V-bottom 384-well plate using ECHO acoustic liquid han...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/18/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 153 total ) | Next | Last >>
Jump to: